Giulio Geraci, Pietro Ferrara, Francesco Pallotti, Rosario Le Moli, Vincenzo Calabrese, Valentina Paternò, Luca Zanoli, Antonina Giammanco, Alessandra Bellavia, Liliana Naro, Alessandra Sorce, Luigi La Via, Jacob George, Riccardo Polosa, Giuseppe Mulè, Caterina Carollo
{"title":"新型肥胖指数与高血压患者左心室肥厚的心电图证据之间的相关性。","authors":"Giulio Geraci, Pietro Ferrara, Francesco Pallotti, Rosario Le Moli, Vincenzo Calabrese, Valentina Paternò, Luca Zanoli, Antonina Giammanco, Alessandra Bellavia, Liliana Naro, Alessandra Sorce, Luigi La Via, Jacob George, Riccardo Polosa, Giuseppe Mulè, Caterina Carollo","doi":"10.3390/jpm15060229","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> Obesity is a key driver of cardiovascular disease (CVD), with central adiposity directly involved in adverse cardiac remodeling. Body mass index (BMI) is limited in capturing fat distribution and associated cardiovascular risk. Novel anthropometric indices, including A Body Shape Index (ABSI) and Body Roundness Index (BRI), may offer greater clinical value, but their relationship with electrocardiographic markers of left ventricular hypertrophy (LVH) remains underexplored. This study aims to assess the correlation between novel adiposity indices (ABSI and BRI) and electrocardiographic evidence of LVH, as measured by the Sokolow-Lyon Index (SLI), in individuals with arterial hypertension. <b>Methods</b>: 274 hypertensive patients were recruited, and BMI, ABSI, and BRI were calculated. LVH was assessed via SLI on 12-lead ECG. Participants were stratified by the SLI (≤35 mm vs. >35 mm) for statistical analyses. <b>Results</b>: Patients with a lower SLI showed significantly higher values of ABSI and BRI compared to those in higher SLI group, without differences in BMI. In the entire population, SLI was significantly and inversely correlated with both ABSI (r = -0.296, <i>p</i> < 0.001) and BRI (r = -0.238, <i>p</i> < 0.01), but not with BMI. Multivariate regression analysis confirmed ABSI (<i>p</i> = 0.013) and BRI (<i>p</i> = 0.038) as independent predictors of SLI, even after adjusting for age, blood pressure, renal function, and metabolic parameters. <b>Conclusions</b>: ABSI and BRI are inversely and independently associated with ECG-derived SLI in hypertensive individuals, suggesting that central adiposity may attenuate ECG voltages and obscure LVH detection. Incorporating novel adiposity indices into ECG interpretation may enhance diagnostic accuracy and risk stratification in obese and hypertensive populations. Longitudinal studies are needed to validate these findings and refine clinical algorithms.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 6","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194296/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correlations Between Novel Adiposity Indices and Electrocardiographic Evidence of Left Ventricular Hypertrophy in Individuals with Arterial Hypertension.\",\"authors\":\"Giulio Geraci, Pietro Ferrara, Francesco Pallotti, Rosario Le Moli, Vincenzo Calabrese, Valentina Paternò, Luca Zanoli, Antonina Giammanco, Alessandra Bellavia, Liliana Naro, Alessandra Sorce, Luigi La Via, Jacob George, Riccardo Polosa, Giuseppe Mulè, Caterina Carollo\",\"doi\":\"10.3390/jpm15060229\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives:</b> Obesity is a key driver of cardiovascular disease (CVD), with central adiposity directly involved in adverse cardiac remodeling. Body mass index (BMI) is limited in capturing fat distribution and associated cardiovascular risk. Novel anthropometric indices, including A Body Shape Index (ABSI) and Body Roundness Index (BRI), may offer greater clinical value, but their relationship with electrocardiographic markers of left ventricular hypertrophy (LVH) remains underexplored. This study aims to assess the correlation between novel adiposity indices (ABSI and BRI) and electrocardiographic evidence of LVH, as measured by the Sokolow-Lyon Index (SLI), in individuals with arterial hypertension. <b>Methods</b>: 274 hypertensive patients were recruited, and BMI, ABSI, and BRI were calculated. LVH was assessed via SLI on 12-lead ECG. Participants were stratified by the SLI (≤35 mm vs. >35 mm) for statistical analyses. <b>Results</b>: Patients with a lower SLI showed significantly higher values of ABSI and BRI compared to those in higher SLI group, without differences in BMI. In the entire population, SLI was significantly and inversely correlated with both ABSI (r = -0.296, <i>p</i> < 0.001) and BRI (r = -0.238, <i>p</i> < 0.01), but not with BMI. Multivariate regression analysis confirmed ABSI (<i>p</i> = 0.013) and BRI (<i>p</i> = 0.038) as independent predictors of SLI, even after adjusting for age, blood pressure, renal function, and metabolic parameters. <b>Conclusions</b>: ABSI and BRI are inversely and independently associated with ECG-derived SLI in hypertensive individuals, suggesting that central adiposity may attenuate ECG voltages and obscure LVH detection. Incorporating novel adiposity indices into ECG interpretation may enhance diagnostic accuracy and risk stratification in obese and hypertensive populations. Longitudinal studies are needed to validate these findings and refine clinical algorithms.</p>\",\"PeriodicalId\":16722,\"journal\":{\"name\":\"Journal of Personalized Medicine\",\"volume\":\"15 6\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194296/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Personalized Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jpm15060229\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15060229","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:肥胖是心血管疾病(CVD)的关键驱动因素,中心性肥胖直接参与不良心脏重构。身体质量指数(BMI)在捕捉脂肪分布和相关心血管风险方面是有限的。新的人体测量指标,包括身体形状指数(ABSI)和身体圆度指数(BRI),可能具有更大的临床价值,但它们与左心室肥厚(LVH)心电图指标的关系仍未得到充分研究。本研究旨在评估动脉高血压患者的新型肥胖指数(ABSI和BRI)与LVH的心电图证据(通过Sokolow-Lyon指数(SLI)测量)之间的相关性。方法:招募274例高血压患者,计算BMI、ABSI、BRI。通过12导联心电图SLI评估LVH。参与者按SLI(≤35 mm vs. >35 mm)分层进行统计分析。结果:低SLI组患者的ABSI和BRI值明显高于高SLI组,BMI值无差异。在整个人群中,SLI与ABSI (r = -0.296, p < 0.001)和BRI (r = -0.238, p < 0.01)呈显著负相关,但与BMI无显著负相关。多因素回归分析证实ABSI (p = 0.013)和BRI (p = 0.038)是SLI的独立预测因子,即使在调整了年龄、血压、肾功能和代谢参数后也是如此。结论:高血压患者的ABSI和BRI与ECG衍生的SLI呈负相关且独立相关,提示中枢性肥胖可能会减弱ECG电压并模糊LVH检测。将新的肥胖指数纳入心电图解释可以提高肥胖和高血压人群的诊断准确性和风险分层。需要纵向研究来验证这些发现并完善临床算法。
Correlations Between Novel Adiposity Indices and Electrocardiographic Evidence of Left Ventricular Hypertrophy in Individuals with Arterial Hypertension.
Background/Objectives: Obesity is a key driver of cardiovascular disease (CVD), with central adiposity directly involved in adverse cardiac remodeling. Body mass index (BMI) is limited in capturing fat distribution and associated cardiovascular risk. Novel anthropometric indices, including A Body Shape Index (ABSI) and Body Roundness Index (BRI), may offer greater clinical value, but their relationship with electrocardiographic markers of left ventricular hypertrophy (LVH) remains underexplored. This study aims to assess the correlation between novel adiposity indices (ABSI and BRI) and electrocardiographic evidence of LVH, as measured by the Sokolow-Lyon Index (SLI), in individuals with arterial hypertension. Methods: 274 hypertensive patients were recruited, and BMI, ABSI, and BRI were calculated. LVH was assessed via SLI on 12-lead ECG. Participants were stratified by the SLI (≤35 mm vs. >35 mm) for statistical analyses. Results: Patients with a lower SLI showed significantly higher values of ABSI and BRI compared to those in higher SLI group, without differences in BMI. In the entire population, SLI was significantly and inversely correlated with both ABSI (r = -0.296, p < 0.001) and BRI (r = -0.238, p < 0.01), but not with BMI. Multivariate regression analysis confirmed ABSI (p = 0.013) and BRI (p = 0.038) as independent predictors of SLI, even after adjusting for age, blood pressure, renal function, and metabolic parameters. Conclusions: ABSI and BRI are inversely and independently associated with ECG-derived SLI in hypertensive individuals, suggesting that central adiposity may attenuate ECG voltages and obscure LVH detection. Incorporating novel adiposity indices into ECG interpretation may enhance diagnostic accuracy and risk stratification in obese and hypertensive populations. Longitudinal studies are needed to validate these findings and refine clinical algorithms.
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.